Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 533-538

  Munster, Pamela N ^a   Moore, Amy P ^a   Ismail Khan, Roohi ^b   Cox, Charles E ^c   Lacevic, Mensura ^b   Gross King, Margaret ^c   Xu, Ping ^c   Carter, W Bradford ^b   Minton, Susan E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; INHIBIN A; INHIBIN B; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRIPTORELIN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GROUPS BY AGE; HUMAN; MENSTRUAL CYCLE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; OVARY FUNCTION; PARTHENOGENESIS; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FERTILITY; FLUOROURACIL; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; INHIBINS; MENSTRUATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARY; PACLITAXEL; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIPTORELIN PAMOATE;

EID: 84856859287     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.6890     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997- 2008, 2001
3. Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1:183-188, 1990 (Pubitemid 20218533)
4. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996 (Pubitemid 26134232)
5. Fornier MN, Modi S, Panageas KS, et al: Incidence of chemotherapy- induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104:1575-1579, 2005 (Pubitemid 41437419)
6. Petrek JA, Naughton MJ, Case LD, et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051, 2006 (Pubitemid 46638800)
7. Tham YL, Sexton K, Weiss H, et al: The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30:126-132, 2007 (Pubitemid 46573245)
8. Davis AL, Klitus M, Mintzer DM: Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of the addition of taxanes. Clin Breast Cancer 6:421-424, 2005 (Pubitemid 43078897)
9. Sukumvanich P, Case LD, Van Zee K, et al: Incidence and time course of bleeding after longterm amenorrhea after breast cancer treatment: A prospective study. Cancer 116:3102-3111, 2010
10. Levine J, Canada A, Stern CJ: Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 28:1-11, 2010
11. Fox KR, Sicallia J, Moore H: Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 22, 2003 (abstr 50)
12. Urruticoechea A, Arnedos M, Walsh G, et al: Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 110:411-416, 2008 (Pubitemid 351962592)
13. Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17:74-78, 2006 (Pubitemid 43033843)
14. Blumenfeld Z, Avivi I, Linn S, et al: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620-1626, 1996 (Pubitemid 26318897)
15. Blumenfeld Z, Benaroush M, Zuckerman T: Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment. Hum Reprod 22:2346, 2007
16. Recchia F, Saggio G, Amiconi G, et al: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106:514-523, 2006 (Pubitemid 43157613)
17. Blumenfeld Z: Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: The role of inhibin-A and -B as markers. Mol Cell Endocrinol 187:93-105, 2002
18. Sowers M, McConnell D, Gast K, et al: Anti- Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 94:1482-1486, 2010
19. Penarrubia J, Peralta S, Fabregues F, et al: Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression. Fertil Steril 94:2590-2595, 2010
20. Beckman Coulter: Inhibin B Gen II ELISA. Brea, CA, 2010
21. Szwarc SE, Bonetti M: Modelling menstrual status during and after adjuvant treatment for breast cancer. Stat Med 25:3534-3547, 2006 (Pubitemid 44575168)
22. Del Mastro L, Boni L, Michelotti A, et al: Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 28:74s, 2010 (suppl; abstr 528)
23. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
24. Gerber B, Stehle H, Ricardo F, et al: ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol 27:13s, 2009 (suppl; abstr 526)
25. Leonard RC, Adamson D, Anderson R, et al: The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 28:89s, 2010 (suppl; abstr 590)
26. Swain SM, Jeong JH, Geyer CE Jr, et al: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065, 2010
27. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
28. Lobo RA: Potential options for preservation of fertility in women. N Engl J Med 353:64-73, 2005
29. Goldman M, O'Hair K: Women's health, breast health: A review of the gynecologic effects of breast cancer. Obstet Gynecol Surv 64:469-480, 2009; quiz 499
30. Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 10:251-266, 2004
31. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006 (Pubitemid 46655598)
32. Oktay K, Sonmezer M: Ovarian tissue banking for cancer patients: Fertility preservation, not just ovarian cryopreservation. Hum Reprod 19:477-480, 2004 (Pubitemid 38344504)